Solid lipid nanoparticles (SLNs) are at the rapidly developed field of nanotechnology with a few potential applications in drug delivery, clinical medication and research, and additionally in other distorted sciences. Because of their small size-subordinate properties, lipid nanoparticles offer the likelihood to grow new therapeutics. The capacity to loaded drugs into nanocarriers offers another model in drug delivery that could be utilized for optional and tertiary levels of drug targeting on. Consequently, SLNs hold extraordinary advantage for achieving the objective of controlled and site specific drug delivery and henceforth have pulled in wide consideration of analysts. The current review describes the role of solid lipid nanoparticles on the pharmacokinetics of poorly soluble antihypertensive drugs. In the event that suitably examined, solid lipid nanoparticles may open new areas in treatment of hypertension with improved oral delivery